Опухоли головы и шеи. 2012; : 59-62
КАПЕЦИТАБИН В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО ПОРАЖЕНИЯ ГОЛОВНОГО МОЗГА У БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ
https://doi.org/10.17650/2222-1468-2012-0-3-59-62Аннотация
В статье рассматривается опыт применения капецитабина у 67 больных раком молочной железы с метастатическим поражением головного мозга (ГМ) (30 больных – применение капецитабина в монорежиме, 30 больных – применение лучевой терапии на ГМ + капецитабин с лечебной целью, 7 больных – применение лучевой терапии на ГМ + капецитабин в адъювантном режиме (после удаления 1 или нескольких солитарных метастазов из ГМ)). Анализировались непосредственная эффективность и отдаленные результаты в группах применения капецитабина в монорежиме, в комбинации с лучевой терапией как с лечебной целью, так и в адъювантном режиме. В группе химиолучевой терапии объективные эффекты (полный эффект, частичный эффект) в ГМ составили 73 %. Медиана времени до прогрессирования – 12,27 мес. В группе монохимиотерапии объективные эффекты (полный эффект, частичный эффект в ГМ) – 30 %. Медиана времени до прогрессирования – 4 мес. Результаты исследования показывают, что капецитабин обладает выраженной противоопухолевой активностью, умеренной токсичностью. Предпочтительным является комбинированный метод лечения.
Список литературы
1. Вестник РОНЦ им. Н.Н. Блохина РАМН, Т. 22, № 3 (85), прил. 1, июль – сентябрь 2011 г.
2. Bendell J.C., Domchek S.M., Burstein H.J. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972–7.
3. Bezjak A., Adam J., Barton R. et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002;38:487–96.
4. Burstein H.J., Lieberman G., Slamon D.J. et al. Isolated central nervous system metastases in patients with HER2- overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005;16:1772–7.
5. Chang E., Lob S. Diagnosis and management of central nervous system metastases from breast cancer. The Oncologist 2003;8(5):398–410.
6. De la Monte S.M., Hutchins G.M., Moore G.W. Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 1984;76:11–7.
7. Heinrich B., Brudler O., Siekiera W. et al. Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 2003;22:37(abstr. 147).
8. Hikino H., Yamada T., Johbara К. et al. Potential role of chemoradiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006;15:97–9.
9. Khuntia D., Brown P., Li J. et al. Wholebrain radiotherapy in the management of brain metastasis. J Clin Oncol 2006;24:1295–304.
10. Lin N.U., Bellon J.R., Winer E.P. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608–17.
11. Oberhoff C., Kieback D.G., Würstlein R. et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001;24:256–60.
12. Rosner D., Flower A., Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma patients: update study. Proc Am Soc Clin Oncol 1993;12:508a.
13. Rosner D., Nemoto T., Lane W.W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58:832–9.
14. Samaan N.A., Buzdar A.U., Aldinger K.A. et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer 1981;47:554–60.
15. Tsao M.N., Lloyd N., Wong R. et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3:CD003869.
16. Siegelmann-Danieli N., Stein M., Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003;5:833–4.
Head and Neck Tumors (HNT). 2012; : 59-62
CAPECITABINE IN THE TREATMENT OF BRAIN METASTATIC LESION IN PATIENTS WITH BREAST CANCER
https://doi.org/10.17650/2222-1468-2012-0-3-59-62Abstract
The paper considers the experience with capecitabine in 67 patients with brain metastatic lesion from breast cancer. The immediate efficacy of capecitabine and the results of therapy with the agent were analyzed in the groups of its use alone and in combination with radiotherapy both for therapeutic purposes and as an adjuvant regimen. In the chemoradiation therapy group, the objective effects in the brain were 73 %. The median time to progression was 12.27 months. In the monochemotherapy group, the objective effects were 30 %. The median time to progression was 4 months. The results of the investigation show that capecitabine has pronounced antitumor activity and moderate toxicity. Combination treatment is the method of choice.
References
1. Vestnik RONTs im. N.N. Blokhina RAMN, T. 22, № 3 (85), pril. 1, iyul' – sentyabr' 2011 g.
2. Bendell J.C., Domchek S.M., Burstein H.J. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972–7.
3. Bezjak A., Adam J., Barton R. et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002;38:487–96.
4. Burstein H.J., Lieberman G., Slamon D.J. et al. Isolated central nervous system metastases in patients with HER2- overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005;16:1772–7.
5. Chang E., Lob S. Diagnosis and management of central nervous system metastases from breast cancer. The Oncologist 2003;8(5):398–410.
6. De la Monte S.M., Hutchins G.M., Moore G.W. Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 1984;76:11–7.
7. Heinrich B., Brudler O., Siekiera W. et al. Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 2003;22:37(abstr. 147).
8. Hikino H., Yamada T., Johbara K. et al. Potential role of chemoradiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 2006;15:97–9.
9. Khuntia D., Brown P., Li J. et al. Wholebrain radiotherapy in the management of brain metastasis. J Clin Oncol 2006;24:1295–304.
10. Lin N.U., Bellon J.R., Winer E.P. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608–17.
11. Oberhoff C., Kieback D.G., Würstlein R. et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 2001;24:256–60.
12. Rosner D., Flower A., Lane W. Chemotherapy induces regression of brain metastases in breast carcinoma patients: update study. Proc Am Soc Clin Oncol 1993;12:508a.
13. Rosner D., Nemoto T., Lane W.W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986;58:832–9.
14. Samaan N.A., Buzdar A.U., Aldinger K.A. et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer 1981;47:554–60.
15. Tsao M.N., Lloyd N., Wong R. et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2006;3:CD003869.
16. Siegelmann-Danieli N., Stein M., Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 2003;5:833–4.
